CHRYSTAL observational study: Socioeconomic costs of type 1 diabetes mellitus in pediatric patients in Spain
Costs related to psoriatic arthritis
Estimation of the economic and social burden of COPD in Extremadura
Chapter on disease burden in the Ankylosing Spondylitis Atlas compared to a new approach
Social return on investment studies
Impacto clínico, asistencial, económico y social del manejo actual de la psoriasis en comparación con un nuevo abordaje. SROI Psoriasis
Impacto clínico, asistencial, económico y social del manejo actual de la insuficiencia cardiaca en comparación con un nuevo abordaje. SROI Insuficiencia Cardiaca
Análisis y validación de la metodología SROI desde la óptica de la Economía de la salud.
Impacto clínico, asistencial, económico y social del manejo actual de la Esclerosis Múltiple en comparación con un nuevo abordaje.
Economic evaluation studies
Estudio piloto de costes y resultados en salud de pacientes con Mieloma Múltiple en un Servicio de Hematología
Análisis Coste-Beneficio de tratamientos para pacientes asmáticos
Estudio de Coste Efectividad de la aplicación del CPAP en pacientes con síndrome de apneas-hipopneas durante el sueño
Coste-efectividad de una unidad monográfica de asma.
Servicio de riesgo cardiovascular en farmacias comunitarias de la provincia de Toledo: Recogida de datos y análisis estadístico
Database exploitation
Explotación de los resultados de la Encuesta Nacional de Salud 2012 de las personas con incontinencia urinaria en España
Explotación de los resultados de la encuesta nacional de salud 2012 de las personas con EPOC en España
Explotación de los resultados de la encuesta nacional de salud 2012 de las personas con Diabetes en España
La obesidad como factor de riesgo de enfermedades crónicas a partir de los datos de la ENS 2012
Calidad de vida, salud autopercibida y consumo de recursos de las personas obesas tipo II y superiores (IMC>35) a partir de la ENS 2012
Explotación de los resultados de la encuesta nacional de salud 2012 de las personas con depresión crónica en España
HEALTH AFFAIRS & POLICY RESEARCH
Health and pharmaceutical policy reports
The evaluation, financing, and regulation of innovative drugs in developed countries
Regulation, financing, and promotion policies for biosimilar drugs in the OECD
The value of medication from a social perspective. Policies for incentivizing generic drugs in the EU
Criteria for financing and reimbursement of orphan drugs
The introduction of biosimilars in Spain: estimation of savings for the National Health System (SNS)
Multi-criteria decision analysis studies
A Multi-Criteria Decision Analysis applied to the field of chronic inflammatory diseases
Multi-Criteria Decision Analysis in the healthcare field: utility and limitations in decision-making
A Multi-Criteria Decision Analysis applied to hereditary angioedema
Analysis of criteria for vaccine procurement in Spain: in search of an ideal sustainable model.
Methodological best practice guides
Methodological Guide for Economic Evaluation applied to orphan drugs
Methodological guide for estimating costs associated with diabetes.
Research studies
Estimation of the administration cost of a biological drug for the treatment of Non-Hodgkin Lymphoma in the NHS
Cost estimation study of intravenous administration of biologicals in Day Hospitals in Spain. The impact of obesity on healthcare resource consumption in Spain
Systematic literature review of economic evaluations of treatments for diabetes mellitus
Cost studies of type 2 diabetes: a literature review
Systematic literature review on the efficacy and safety of metformin in patients with Type 2 Diabetes Mellitus
Applicability of multi-indication pricing
A critical analysis of value-based oncology frameworks using the example of metastatic prostate cancer
Adaptation to the Spanish National Health System of the cost-utility analysis of a treatment for patients diagnosed with prostate cancer
Adaptation to CatSalut of the cost-utility analysis of a treatment for patients diagnosed with prostate cancer
Cost-Minimization Analysis of a treatment for Acute Lymphoblastic Leukemia
Adaptation for Spain of the cost-utility analysis of a drug for Gaucher’s disease
Adaptation to the Spanish National Health System of the cost-effectiveness analysis of a drug for the treatment of acute postoperative pain
Adaptation to the Spanish National Health System of the cost-effectiveness analysis of a drug for the treatment of gastrointestinal stromal tumors
Adaptation of the cost-utility analysis of a drug for the treatment of limbal stem cell deficiency
Adaptation of a cost-utility analysis of a drug for the treatment of schizophrenia
Cost-effectiveness analysis of the use of a medical device in stress urinary incontinence
Cost-effectiveness analysis of a drug for the treatment of hyperphosphatemia in chronic kidney disease in Spain
Development of the cost-utility analysis of oral anticoagulants in atrial fibrillation
Cost-utility analysis of transdermal patches in the treatment of post-herpetic neuralgia
Cost-effectiveness analysis of a drug for the treatment of stable chronic angina Economic evaluation of second-generation low molecular weight heparin for primary prevention of venous thromboembolism after total hip or knee arthroplasty
Adaptation to the Spanish National Health System of a cost-minimization analysis of a drug for the treatment of chronic nephropathy
Cost-utility analysis of an anti-TNF biological drug in the treatment of rheumatoid arthritis
Adaptation to the Spanish National Health System of a cost-effectiveness analysis of an anti-TNF biological drug for the treatment of psoriatic arthritis
Adaptation to the Spanish National Health System of a cost-effectiveness analysis of an anti-TNF biological drug for the treatment of axial spondyloarthritis
Adaptation of the budget impact analysis of a chemotherapeutic drug for the treatment of advanced breast cancer in Spain.
Adaptation of the budget impact analysis to the autonomous communities of the budget impact of a chemotherapeutic drug for the treatment of advanced breast cancer
Budget Impact (BIM) Analysis and assessment of relevant variables in Spain for the development of an economic model in pulmonary arterial hypertension
Adaptation to the Spanish National Health System of the budget impact analysis of a treatment for patients diagnosed with prostate cancer
Adaptation to CatSalut of the budget impact analysis of a treatment for patients diagnosed with prostate cancer Programming of the budget impact of a treatment for patients diagnosed with prostate cancer in iPad format
Budget Impact Analysis of a treatment for Acute Lymphoblastic Leukemia Adaptation to the Spanish National Health System of the budget impact analysis of a treatment for hemophilia B Development of a budget impact for a drug for the treatment of hemophilia A and B in Spain
Adaptation to the Spanish National Health System of the budget impact analysis of a drug for the treatment of gastrointestinal stromal tumors
Budget impact of the use of glucose meters with higher accuracy
Adaptation for Spain of the long-term budget impact analysis of increased longevity of an implantable automatic defibrillator
Development of the budget impact analysis of a drug for the prophylaxis of renal transplant rejection
Development of a budget impact model for the introduction of a drug in the prophylactic treatment of graft rejection in renal transplantation in Spain
Adaptation to the Spanish National Health System of the budget impact analysis of a drug for the treatment of an ultra-rare disease
Price and financing dossiers
Development of the pricing and reimbursement dossier for a treatment for Acute Lymphoblastic Leukemia
Development of the pricing and reimbursement dossier for the treatment of hemophilia B in Spain
Development of the pricing and reimbursement dossier for the treatment of hemophilia A and B in Spain
Adaptation to Spain of the international value dossier developed for a drug for the treatment of Gaucher’s disease
Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of acute postoperative pain
Development of a clinical and economic value dossier for a thickening agent for the management of patients with dysphagia in Spain
Development of a Value dossier for a drug for patients with asthma and COPD
Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of gastrointestinal stromal tumors
Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of cystic fibrosis
Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of COPD
Value dossier for a drug for the treatment of hyperphosphatemia in chronic kidney disease in Spain
Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of limbal stem cell deficiency
Adaptation to the Spanish National Health System of the value dossier for a drug for the treatment of an ultra-rare disease
Development of a value dossier for a drug for the treatment of schizophrenia
Value dossier for a drug for the treatment of sickle cell anemia in Spain
Adaptation to the Spanish National Health System of the value dossier for an anti-TNF biological drug for the treatment of psoriatic arthritis
Adaptation to the Spanish National Health System of the value dossier for an anti-TNF biological drug for the treatment of axial spondyloarthritis
Value dossier for a chemotherapeutic drug for the treatment of advanced breast cancer in Spain
Adaptation to the autonomous communities of the value dossier for a chemotherapeutic drug for the treatment of advanced breast cancer
Pre IPTs
Development of a Therapeutic Positioning Report for a drug for schizophrenia
Development of a Therapeutic Positioning Report for a drug for acquired hemophilia
Development of a Therapeutic Positioning Report for a drug for Acute Lymphoblastic Leukemia
Development of a Therapeutic Positioning Report for a drug for Gaucher’s disease
Development of a Therapeutic Positioning Report for a drug for the treatment of COPD
Development of a Therapeutic Positioning Report for a drug for the treatment of limbal stem cell deficiency
Development of a Therapeutic Positioning Report for a drug for the treatment of schizophrenia
Development of a Therapeutic Positioning Report for a chemotherapeutic drug for advanced breast cancer
Databases
Database of direct and indirect costs of diabetes in five European countries: Germany, Spain, France, Italy, and the United Kingdom
Database of direct costs associated with chronic pain in Spain
Database of direct costs of psoriatic arthritis in 6 countries: Germany, Spain, United States, France, Italy, and the United Kingdom
Database of direct costs of multiple sclerosis in the United States
Database of direct costs of castration-resistant metastatic prostate cancer in France
Database of direct healthcare costs of non-valvular atrial fibrillation in Mexico and Russia
Database of direct costs of multiple myeloma in four European countries: Germany, Spain, France, and Italy
Database of direct costs of hemophilia in five European countries: Germany, Spain, France, Italy, and the United Kingdom
Database of direct and indirect costs of osteoporosis in Denmark
Database of direct and indirect costs of rheumatoid arthritis in: Denmark, Germany, Spain, France, Hungary, Italy, Poland, Romania, Sweden, and the United Kingdom Stakeholders
Database in Oncology-Hematology Stakeholders Database in Biosimilars in Dermatology
Cost calculators
Study of costs in cutaneous psoriasis and other dermatological conditions
Development of a budget impact analysis of mesenchymal stem cell treatment in five chronic diseases throughout the patient’s lifetime
Costs of type II diabetes mellitus: GECOD model
Programming of type II diabetes mellitus costs on iPad: GECOD model
Disease burden models
Estimation of the improvement in quality of life and years of life gained in atypical hemolytic uremic syndrome following the introduction of a drug in Spain
The introduction of biosimilars in Spain. Estimation of savings for the National Health System
Long-term fiscal impact of Assisted Reproductive Therapies in Spain
Economic burden of type II diabetes mellitus: GECOD model
Programming of economic burden of type II diabetes mellitus on iPad: GECOD model
The economic burden of epithelial ovarian cancer in Spain: OVARCOST study
Product monographs
Monograph of an anti-TNF biological drug. Clinical and pharmacoeconomic attributes in dermatology
Monograph of a drug for cystic fibrosis
HEALTH IMPACT ASSESMENT
MEDICAL EDUCATION, PRESS & PUBLISHING
Continuous training of the SNS
How to conduct an Economic Evaluation study and publish it?
Economic evaluation of medications: practical applications for a regional pharmacy service
Economic evaluation: practical applications in the hospital setting
Economic evaluation: from theory to practice. Tools for conducting Economic Evaluation and budget impact studies
Review of Economic Evaluation studies: practical workshop on critical reading
Economic evaluation of medications: practical applications for a Health Department
Leadership and management course for Hematology department heads. Orphan drugs in the current healthcare environment
Economic evaluation of medications: practical applications for Primary Care Pharmacists
Leadership and management course: Building confidence to achieve results
In-person course for primary care pharmacists. GRADE method
Pharmacoeconomics for hematologists
Economic evaluation for professionals in the Public Administration of the National Health System
In-person and online course for primary care pharmacists
Critical analysis of advances in Economic Evaluation
Network meta-analysis and R program
In-person training course on SPSS
Online course for neurologists
Economic Evaluation Workshops: Generics and by Medical Specialty
Pharmacoeconomics Workshops for Pulmonologists and Allergists
Pharmacoeconomics Workshops for Hematologists
Pharmacoeconomics Workshops for Hospital
Pharmacists Pharmacoeconomics Workshops in Rheumatology
Pharmacoeconomics Workshops in Ophthalmology
Training Workshop on Economic Evaluation of Drugs for Rare Diseases
Pharmacoeconomics Workshops applied to Urologists
Pharmacoeconomics Workshops applied to Oncology and Hematology Medications
Pharmacoeconomics Workshops for HIV Specialists
Pharmacoeconomics Workshops. New Challenges in Prostate Cancer: From Clinical Practice to Pharmacoeconomics
Pharmacoeconomics Workshops applied to Clinicians and Pharmacists of SESCAM (Healthcare Service of Castilla-La Mancha)
The Role of Pharmacoeconomics in Decision-making for Food Supplementation
Pharmacoeconomics Workshop for Pharmaceutical Care Units (FAP)
Workshop on Agreements and Financing
Pharmacoeconomics Workshop for Public Health Technicians
Workshop on Social Media and Professional Opportunities for FIR (Pharmaceutical Internship Resident)
In-Company Training
Economic Evaluation of Drugs and Optimal Market Access Strategies
Pharmacoeconomics and Market Access Training for Specialized Sales Force in the Respiratory Area
Pharmacoeconomics and Market Access Training for the Sales Network of a Specific Product Line
Economic Evaluation of Devices and Optimal Market Access Strategies
The Role of Pharmacoeconomics in Decision Making
Economic Evaluation of Drugs and Optimal Market Access Strategies
Debate sessions
Pharmacoeconomics and its Role in the Therapeutic Positioning of Oncology Drugs in Clinical Practice Guidelines
Pharmacoeconomics Applied to Decision Making
Pharmacoeconomics Workshop for Hospital Pharmacists, Oncologists, and Hematologists. Murcia
Pharmacoeconomics and its Role in the Therapeutic Positioning of Onco-Hematological
Drugs in Andalusia
Economic Evaluation for Oncologists in the National Health System
Healthcare Professionals and the Future of Healthcare in Spain
Aragon: Pharmacological Innovations in Oncology and Economic Efficiency: What Should We Consider?
Castilla y León: Pharmacological Innovations in Oncology and Economic Efficiency: What Should We Consider?
Decision Making Based on Health Outcomes
Innovation, Quality of Care, Humanization, and Sustainability
Humanization and Healthcare Delivery
Workshop on Innovative Contracting Agreements in the Healthcare Sector
Workshop on HTA Cooperation in Europe: Towards a Stable Model
PUBLICATIONS
Books
Health Assessment Notebooks
Applied Pharmacoeconomics Book in Hematology
White Paper on the Socioeconomic Burden of COPD
Methodological Guide for Estimating Costs Associated with Diabetes
Methodological Guide for Economic Evaluation Applied to Orphan Drugs
White Paper on the Socioeconomic Burden of Urinary Incontinence in Spain
White Paper on the Socioeconomic Burden of Prostate Cancer in Spain
Multi-Criteria Decision Analysis in the Healthcare Field: Utility and Limitations in Decision Making
